QRX003, 4% Lotion

DRUG2 trials

Sponsors

Quoin Pharmaceuticals

Conditions

Netherton Syndrome

Phase 2

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

RecruitingNCT05789056

Quoin PharmaceuticalsNetherton Syndrome

Start: 2023-03-14End: 2026-12-30Target: 20Updated: 2026-08-31

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

RecruitingNCT06953466

Quoin PharmaceuticalsNetherton Syndrome

Start: 2025-10-06End: 2026-12-30Target: 8Updated: 2026-08-31